Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma in adults, and is characterized as clinically and biologically heterogeneous lymphomas with diverse response to therapy and variation in clinical behavior. It's well-established that c-MYC and BCL2 play important roles in normal B-cell differentiation and tumorigenesis. B cell lymphoma with dual expression of c-MYC and BCL2 (double-expressor lymphoma, DEL) accounts for approximately one-third of DLBCL cases. DEL patients have poor outcomes after chemoimmunotherapy or autologous stem-cell transplantation. Lack of a genetic mouse tool for DEL hinders us from understanding the lymphogenesis mechanism and developing therapeutic strategies. Here, we investigated whether ectopic expression of c-MYC and BCL2 in different stages of B cells could lead to lymphoma and generate a mouse model for DEL. We observed that Co-expression of c-MYC and BCL2 in germinal center (GC) B cells, or pan-B cells could induce B cell lymphomas. The tumor-bearing mice have enlarged lymphoid organs, and B cells massively infiltrate into non-lymphoid organs including lung, liver and kidney. The tumor-bearing mice also manifested significantly shorter lifespan than the controls. In addition, adoptive transfer of Co-expression B cells leads to B cell lymphoma and host mice death. This model will provide us a tool to further explore the pathogenesis and treatment approaches for DEL.

Highlights

  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the USA, and it accounts for 24% of newly diagnosed NHL cases each year [1]

  • The results described here establish a clinically relevant mouse model of double-expressor lymphoma by targeting constitutive expression of c-MYC and BCL2

  • We observed that Co-expression of c-MYC and BCL2 in germinal center B cells, or pan-B cells could both induce B cell lymphoma

Read more

Summary

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the USA, and it accounts for 24% of newly diagnosed NHL cases each year [1]. For the patients who are refractory to up-front treatment, or relapse after achieving remission, the outcomes are poor [2]. In the Murine Model for Double-Expressor Lymphoma revised 2016 World Health Organization classification of lymphoid neoplasms, Co-expression of c-MYC and BCL2 was considered as a new subgroup and defined as doubleexpressor lymphoma (DEL), which accounts for approximately one-third of DLBCL cases [5]. DEL patients with aggressive B cell lymphomas have poor outcomes after standard upfront treatment [7]. DEL is associated with inferior outcomes after autologous stem-cell transplantation in patients with relapsed or refractory DLBCL [8]. DEL mouse model is urgently needed to study in-depth mechanism of pathogenesis and develop new therapeutic approaches

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call